Research Upregulation of CD23 (FcεRII) Expression in Human Airway Smooth Muscle Cells (huASMC) in Response to IL-4, GM-CSF, and IL-4/GM-CSF by Belleau, Joseph T et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Clinical and Molecular Allergy
Open Access Research
Research Upregulation of CD23 (Fcε RII) Expression in Human 
Airway Smooth Muscle Cells (huASMC) in Response to IL-4, 
GM-CSF, and IL-4/GM-CSF
Joseph T Belleau†, Radha K Gandhi†, Holly M McPherson and D Betty Lew*
Address: Department of Pediatrics, Children's Foundation Research Center at the Le Bonheur Children's Medical Center, University of Tennessee 
Health Science Center, 50 North Dunlap Street, Rm401, WPT, Memphis, TN 38103, USA
Email: Joseph T Belleau - jcbelleau@yahoo.com; Radha K Gandhi - rgandhi@utmem.edu; 
Holly M McPherson - HMCPHERSON@PIEDMONTALLERGY.COM; D Betty Lew* - dlew@utmem.edu
* Corresponding author    †Equal contributors
Abstract
Background: Airway smooth muscle cells play a key role in remodeling that contributes to airway
hyperreactivity. Airway smooth muscle remodeling includes hypertrophy and hyperplasia. It has
been previously shown that the expression of CD23 on ASMC in rabbits can be induced by the IgE
component of the atopic serum. We examined if other components of atopic serum are capable
of inducing CD23 expression independent of IgE.
Methods: Serum starved huASMC were stimulated with either IL-4, GM-CSF, IL-13, IL-5, PGD2,
LTD4, tryptase or a combination of IL-4, IL-5, IL-13 each with GM-CSF for a period of 24 h. CD23
expression was analyzed by flow cytometry, western blot, and indirect immunofluorescence.
Results: The CD23 protein expression was upregulated in huASMC in response to IL-4, GM-CSF,
and IL-4/GM-CSF. The percentage of cells with increased fluorescence intensity above the control
was 25.1 ± 4.2% (IL-4), 15.6 ± 2.7% (GM-CSF) and 32.9 ± 13.9% (IL-4/GMCSF combination)(n = 3).
The protein content of IL-4/GMCSF stimulated cells was significantly elevated. Expression of CD23
in response to IL-4, GM-CSF, IL-4/GM-CSF was accompanied by changes in cell morphology
including depolymerization of isoactin fibers, cell spreading, and membrane ruffling. Western blot
revealed abundant expression of the IL-4Rα  and a low level expression of IL-2Rγ c in huASMC.
Stimulation with IL-4 resulted in the phosphorylation of STAT-6 and an increase in the expression
of the IL-2Rγ c.
Conclusion:  CD23 on huASMC is upregulated by IL-4, GM-CSF, and IL-4/GM-CSF. The
expression of CD23 is accompanied by an increase in cell volume and an increase in protein content
per cell, suggesting hypertrophy. Upregulation of CD23 by IL-4/GM-CSF results in phenotypic
changes in huASMC that could play a role in cell migration or a change in the synthetic function of
the cells. Upregulation of CD23 in huASMC by IL-4 and GM-CSF can contribute to changes in
huASMC and may provide an avenue for new therapeutic options in asthma targeting ASMC.
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Background
Chronic inflammation and airway smooth muscle dys-
function are consistent features of asthma responsible for
disease progression and airway remodeling [1]. The
increase in bronchial smooth muscle, both hypertrophy
[2] and hyperplasia [3], plays a critical role in the develop-
ment of airway hyperreactivity (AHR), the hallmark of
asthma. Airway smooth muscle cells (ASMC) may also
play a secretory or immunomodulatory role by producing
pro-inflammatory cytokines, chemokines, polypeptide
growth factors, extracellular matrix proteins, cell adhesion
receptors, and co-stimulatory molecules, which perpetu-
ate submucosal inflammation [4,5]. These mediators may
act on the ASM itself in an autocrine manner as well to fur-
ther contribute to the asthma phenotype [6]. Therefore,
smooth muscle itself may be capable of initiating and
maintaining airway inflammation. Also, ASMC have been
shown to undergo cell migration, which could contribute
to airway remodeling [7]. Thus, regulation of airway
smooth muscle hypertrophy and migration may be a new
target for treatment of asthma [7,8].
It is well known that IgE plays a critical role in the patho-
genesis of asthma in the early and late phases by interact-
ing with its two receptors, the high affinity receptor
(Fcε RI) and the low affinity receptor (Fcε RII) [9]. IgE plays
a key role in bronchial hyperresponsiveness and smooth
muscle hyperreactivity [8]. Crosslinking of the high affin-
ity IgE receptor (Fcε RI) on mast cells leads to cellular
degranulation and the release of various proinflammatory
mediators and cytokines contributing to bronchoconstric-
tion. The low affinity IgE receptor (CD23) (Fcε RII) has
been identified on B cells, monocytes, follicular dendritic
cells, Langerhan's cells, eosinophils, and platelets [10].
Upregulation of the CD23 receptor is thought to increase
allergic responses in the bronchial mucosa through the
enhancement of antigen uptake and presentation [8]. The
receptor has two isoforms that differ only in their cyto-
plasmic domains [11]. CD23a is constitutively expressed
on B cells and is associated with endocytosis of IgE coated
particles, and CD23b is induced by IL-4 and is also found
on non- B cells such as T cells, Langerhan's cells, mono-
cytes, macrophages, platelets, and eosinophils [12,13]. IL-
4 causes CD23 induction on B cells through CD40 [12].
CD23b mediates phagocytosis of soluble IgE complexes.
An autocatalytic process involving cleavage of membrane
bound CD23 by a matrix metalloprotease yields a series of
soluble elements (sCD23) which increase IgE production
via the CD21 receptor on B cells [13,14].
The CD23 receptor has been shown to be upregulated on
monocytes and alveolar macrophages in a T helper cell
type 2 (TH2) environment and may contribute to chronic
inflammation in asthma through this mechanism [15]. It
has been shown that IL-4 and GM-CSF induce CD23
expression on monocytes, and GM-CSF primes mono-
cytes for cellular activation and secretion of IL-1 upon
subsequent exposure to IgE-containing immune com-
plexes [8]. CD23 is also involved in antigen presentation
to B cells as well as cellular interactions between B and T
cells [12].
In previous studies, Hakonarson et al. [16] demonstrated
the expression of CD23 (Fcε RII) messages and a low level
of the protein in airway smooth muscle cells. In two
patients who died of status asthmaticus, CD23 expression
was also markedly upregulated on ASMC. The CD23
expression was inducible with human atopic sera or IgE
immune complexes in naïve (control) ASMC, and this
upregulation was blocked when pretreated with anti-
CD23 blocking antibody. The authors concluded that IgE
coupled activation of CD23 contributes largely to its
upregulation [5,14]. In a corresponding experiment with
rabbit ASMC subjected to control and atopic serum, they
were able to demonstrate, through Western blot analysis,
a markedly enhanced expression of CD23 in the ASMC
sensitized with atopic serum or IgE immune complexes.
They were able to achieve significant inhibition of upreg-
ulation by pretreatment with anti-CD23 mAb. They
hypothesized that IgE was responsible for the upregula-
tion of the low affinity IgE receptor [17]. Hakonarson, et
al. have also demonstrated that ASMC in vitro exposed to
human atopic sera results in an initial increase in TH2
cytokines including IL-5 and GM-CSF followed hours
later by production of IL-1 and TH1 cytokines [18,19].
Recently, phase I trials have been completed on IDEC-
152, an IgG1 anti-CD23 antibody, for patients with mild
to moderate persistent asthma. The drug was well toler-
ated by participants, and a dose-dependent decrease in
mean IgE values was reported [20].
T helper cell type 2 (TH2) mediated inflammatory
cytokines, such as IL-4, IL-13, and IL-5, as well as other
enzymes and chemokines are active in the asthmatic
patient. GM-CSF has been shown to be involved in
asthma pathogenesis and in vivo can induce TH2 differen-
tiation independent of IL-4 [21]. Tryptase and prostagla-
din D2 (PGD2) were chosen as major mast cell mediators,
and more recently the PGD2 receptor gene (PTGDR) has
been shown to be an asthma susceptibility gene [22-24].
It is possible that many factors are responsible for the
upregulation of the low affinity IgE receptor in addition to
and independent of IgE. The purpose of this study was to
identify specific mediators released in the asthmatic
patient that are responsible for the upregulation of CD23
on human airway smooth muscle cells independent of
IgE.Clinical and Molecular Allergy 2005, 3:6 http://www.clinicalmolecularallergy.com/content/3/1/6
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Methods
Cell culture and flow cytometry
Alpha-smooth muscle isoactin positive Human ASMC
(Cambrex, Walkersville, MD) in T-75 flasks were starved
for 24 hours in 0.1% (vol/vol) fetal bovine serum (FBS)
containing medium M199 (Cellgro, Herndon, VA) sup-
plemented with 1% (vol/vol) antibiotic/antimycotic solu-
tion (Sigma Chemical Co., St Louis, MO). The cells were
then stimulated with either vehicle (bovine serum albu-
min, BSA, vehicle for cytokines (1 mg/ml), in M199; eth-
anol (EtOH), vehicle for LTD4 (6% final concentration)
and PGD2 (0.001–0.01% final concentration); M199,
vehicle for tryptase), an individual mediator, or a media-
tor in combination with GM-CSF at their optimum con-
centrations for 24 hours. The doses of cytokines used were
up to four time ED50 including: IL-4 (0.04–1 nM), GM-
CSF (0.07–0.8 nM), IL-13 (0.4 nM), IL-5 (0.01–0.07 nM),
IL-13 (0.3–2.2 nM), PGD2 (1–10 µM), LTD4 (1–10 µM),
tryptase (30 nM, a concentration sufficient to induce
ASMC proliferation) (Sigma). Dose ranging studies were
performed to determine the optimum concentration of
IL-4 and GM-CSF on the expression of CD23, and the
doses chosen were IL-4 (0.5 nM) and GM-CSF (0.4 nM)
(Figure 1). All cytokines were obtained from R & D Sys-
tems Inc. Minneapolis, MN except GM-CSF which was
obtained from Sigma. The cells were then harvested with
a soft rubber edged scraper, centrifuged for 5 minutes at
1000 rpm (200 g), washed and resuspended in 1% BSA in
phosphate buffered saline (PBS) and fixed with 70%
ETOH. After washing twice more, the cells were resus-
pended in 1% BSA in PBS. Finally, they were filtered
through a 40 µm nylon mesh to obtain single cell suspen-
sion and stained with (20 µl) of PE (phycoerythrin)-CD23
(EBVCS-5, BD Biosciences, San Jose, CA) or PE-mouse
IgG1 for 15 minutes in the dark to facilitate staining for
flow cytometry.
Upregulation of CD23 by IL-4 and GM-CSF Figure 1
Upregulation of CD23 by IL-4 and GM-CSF. Dose-ranging studies were performed to determine the optimum concen-
trations of IL-4 and GM-CSF. Alpha-smooth muscle isoactin positive Human ASMC (Clonetics) in T-75 flasks were starved for 
24 h in 0.1% FBS containing medium M199. The cells were then stimulated with BSA (1 µg/ml), IL-4 (0.125. 0.25, 0.5, or 1.0 nM) 
or GM-CSF (0.1, 0.2, 0.4, or 0.8 nM) for 24 h. The cell lysates in RIPA buffer were subjected to western blot analysis for CD23. 
Mouse anti-human CD23 monoclonal antibody (clone M-L233, BD Biosciences, 1 µg/5 ml) was used as the primary antibody 
and anti-mouse horseradish peroxidase linked antibody as the secondary antibody (Amersham). The immunoreactive protein 
bands were detected by enhanced chemiluminescence light (ECL) (Amersham).
IL IL- -4( 4( nM nM) 0.125 0.25 0.5 1.0 ) 0.125 0.25 0.5 1.0 24hr 24hr
GM GM- -CSF ( CSF (nM nM) 0.1 0.2 0.4 0.8_ ) 0.1 0.2 0.4 0.8_
- -CD23 (45 CD23 (45 kD kD) )
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Protein analysis
A commercially available bicinchoninic acid (BCA) kit
(Pierce, Rockford, IL) was used for protein analysis
according to the manufacturer's instructions. The optical
densities were read using a Bio-Kinetics EL-312 Micro-
plate reader.
Indirect immunofluorescence
Indirect immunofluorescence stainings were performed
with anti-smooth muscle-α  isoactin antibody (Sigma)
and anti-human CD23 antibody (M-L233, 1 µg/ml, BD
Biosciences), which are specific monoclonal antibodies
and either a FITC or TRITC fluorochrome, conjugated sec-
ond antibody. Fixed huASMC were incubated with the
above antibodies diluted in PBS with 3% BSA for 60 min
at room temperature. The cells were then washed three
times with PBS for 10 minutes for each wash. Non-specific
binding was blocked by incubating cells with 3% BSA in
PBS for 60 minutes. The blocking solution was then
removed and cells were incubated with FITC- or TRITC-
fluorochrome conjugated antibody for 45 minutes in the
dark to facilitate staining. Cells were then washed with
PBS three times. Finally, one drop of Fluoromount-G
(Southern Biotechnology Inc., Birmingham, AL) was
added.
Western blot
Standard Western blot analyses were performed to detect
anti-STAT6 (1:500, Calbiochem, San Diego, CA) polyclo-
nal rabbit, anti-p-STAT-6 (1:500, Calbiochem) polyclonal
rabbit. Human ASMC lysates in radio-immunoprecipita-
tion assay (RIPA) buffer were transferred onto Hybond-
ECL nitrocellulose membranes and were immunoblotted
with monoclonal anti-human CD23 (1:500 dilution,
clone M-L233, 1 µg/5 ml, BD Biosciences), polyclonal
anti-IL-4Rα  (1:500 dilution, Santa Cruz), monoclonal
anti-IL-2Rγ c (1:250 dilution, R&D Systems, Inc.). The
nitrocellulose membranes were incubated with a 1:1,000
dilution of anti-rabbit or anti-mouse horseradish peroxi-
dase linked whole antibody (Amersham, Piscataway, NJ)
in PBS-T for 1 hour at room temperature. Paxillin mono-
clonal antibody (1:500 dilution, Transduction Laborato-
ries) was used as a positive isotype control for CD23, and
fibronectin polyclonal antibody (1:250, Sigma) was used
as a positive control for the remaining antibodies. The
immunoreactive protein bands were detected by
enhanced chemiluminescence light (ECL) (Amersham).
Statistical analysis
Data were analyzed with Prism 4 software (GraphPad, San
Diego, CA). One-way analysis of variance (ANOVA) was
used. Results are expressed as mean ± SEM. A P value less
than 0.05 was considered statistically significant.
Results
CD23 protein expression is upregulated in huASMC by IL-
4, GM-CSF, or IL-4/GM-CSF
Previous studies have shown that IgE immune complexes
in atopic serum caused an increase in CD23 expression in
ASMC [16]. To determine if other humoral factors in
atopic serum effect CD23 expression in human ASMC, we
have tested the effect of the relevant cytokines, arachi-
donic acid metabolites, and the mast cell enzyme tryptase.
Flow cytometry was performed to evaluate differences in
cell populations after stimulation of the huASMC for 24
hours with either individual mediators IL-4 (0.5 nM),
GM-CSF (0.4 nM), IL-13 (0.4 nM), IL-5 (0.4 nM), PGD2
(10 µM), LTD4 (10 µM), tryptase (30 nM) or a combina-
tion of IL-4, IL-5, and IL-13 each with GM-CSF. Within the
huASMC stimulated by IL-4, GM-CSF or the combination
of IL-4/GM-CSF, two populations of cells were detected
distinguishable by cell size. While the smaller cells did not
show a significant expression of CD23, many of the larger
cells showed increased expression of CD23. In the exam-
ple in Figure 2, 66% of the larger cells (gate D) showed an
increase in cell expression of CD23 when compared to the
controls. As stated previously, the functions of ASMC are
heterogeneous including proliferation and synthesis. Pre-
vious studies have shown, on flow cytometry of ASMC
stimulated in vitro with IL-1β  and TNF-α , only 20–60% of
ASMC produce GM-CSF. The ASMC producing GM-CSF
include some which also have increased proliferative
properties. This suggests that considerable heterogeneity
exists in the phenotypic expression of the ASMC in culture
[25].
In addition to the combination of IL-4/GM-CSF inducing
increased expression of CD23, both IL-4 and GM-CSF
alone independently increased the expression of CD23 in
huASMC. The percentage of cells with increased fluores-
cence intensity above the control was 25.1 ± 4.2% (IL-4),
15.6 ± 2.7% (GM-CSF) and 32.9 ± 13.9% (IL-4/GM-CSF
combination). On the other hand, IL-5, IL-13, cysteinyl
leukotrienes, and tryptase did not induce CD23 expres-
sion (Table 1).
Expression of CD23 in response to IL-4, GM-CSF, IL-4/GM-
CSF is accompanied by changes in huASMC morphology
Western blot analysis of huASMC stimulated with IL-4,
GM-CSF, or Il-4/GM-CSF for 24 h showed an increase in
CD23 expression compared to BSA vehicle control (Figure
3). Indirect immunofluorescence was used also to identify
any morphological changes associated with the cytokine
stimulation and upregulation of CD23 (Figure 4A–D).
Those cells stimulated with the combination of IL-4/GM-
CSF demonstrated CD23 expression along with changes
in cell morphology including depolymerization of isoac-
tin fibers, cell spreading, and membrane ruffling (Figure
4B). These changes in phenotype are consistent with flowClinical and Molecular Allergy 2005, 3:6 http://www.clinicalmolecularallergy.com/content/3/1/6
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cytometry results in that the larger cells expressed CD23
(Figure 4D). In contrast, the control BSA stimulated pop-
ulation showed no changes in cell cytoskeletal structure
and morphology (Figure 4A) or specific staining for CD23
(Figure 4C).
To confirm activity of protein synthesis, the protein con-
tent of the control and the experimental groups of cells
were compared using a BCA protein analysis kit. Human
ASMC were starved for 24 hours in 0.1% FBS containing
medium M199 and then stimulated with BSA (1 µg/mL),
IL-4 (0.5 nM), GM-CSF (0.4 nM), or IL-4 (0.5 nM)/GM-
CSF (0.4 nM) for 24 hours. The protein content was
increased by 19% in the IL-4/GM-CSF treated cells above
that of the control (Table 2). The increase in protein con-
centration with IL-4 alone was not statistically significant.
Stimulation of huASMC with IL-4 induces phosphorylation 
of STAT-6 and expression of IL-2Rγ c
IL-4 binds the IL-4R with high affinity, and signaling
through IL-4 causes enhanced expression of IL-4R [21].
The induction of these genes is mediated through signal
transduction molecules including signal transducer acti-
vator of transcription (STAT-6). The binding of IL-4 to its
receptor complex induces the formation of an IL-4 recep-
tor complex which consists of IL-4Rα  and the common
gamma chain (γ c) of the receptors for IL-2, IL-4, IL-7, IL-
9, IL-15, and IL-21 [21]. It has not been previously
Upregulation of CD23 by IL-4, GM-CSF and IL-4/GM-CSF Figure 2
Upregulation of CD23 by IL-4, GM-CSF and IL-4/GM-CSF. Alpha-smooth muscle isoactin positive Human ASMC 
(Clonetics) in T-75 flasks were starved for 24 h in 0.1% FBS containing medium M199. The cells were then stimulated with IL-
4 (0.5 nM)/GM-CSF (0.4 nM) for 24 h. The FACS analysis showed that the smaller cells passed through Gate A and larger cells 
passed through Gate D. Background noise was eliminated using the BSA-stimulated control cells that were labeled with PE-
anti-CD23 (EBVCS), represented by C in Gate A, and F in Gate D. The FACS results of a representative experiment showed 
66% of the larger cells (Gate D) had an increase in cell expression of CD23 when compared to the controls.
Fluorescence Intensity Fluorescence Intensity
Gate A Gate D
Gate A
Gate DClinical and Molecular Allergy 2005, 3:6 http://www.clinicalmolecularallergy.com/content/3/1/6
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Table 1: Il-4, GM-CSF, and IL-4/GM-CSF Increase CD23 Expression on ASMC (n = 3)
Cytokine (24 hours) #Cells in Gate D 
(n = 3)
%Cells with Increased CD23 
Expression Above the Control
BSA (1 µg/ml) 1,343 ± 122 0
IL-4 (0.5 nM) 1,413 ± 197 25.1 ± 4.2*
GM-CSF (0.4 nM) 1,346 ± 243 15.6 ± 2.7*
IL-4/GM-CSF (0.4/0.5 nM) 1,324 203 32.9 ± 13.9*
IL-5 (0.4 nM) 1,130 ± 251 0
IL-13 (0.4 nM) 1,316 ± 269 0
PGD2 (1 µM) 1,521 ± 123 0
PGD2 (10 µM) 1,159 ± 204 0
LTD4 (10 µM) 2,037 ± 375 0
Ethanol (6% vol/vol) 2,507 ± 200 0
Tryptase (10 µM) 2,385 ne ± 405 0
Alpha-smooth muscle isoactin positive Human ASMC (Clonetics) in T-75 flasks were starved for 24 h in 0.1% FBS containing medium M199. The 
cells were then stimulated with BSA (1 µg/ml), IL-4 (0.5 nM), GM-CSF (0.4 nM), IL-4 (0.5 nM)/GM-CSF (0.4 nM), IL-13 (0.4 nM), IL-5 (0.4 nM), 
PGD2 (10 µM), LTD4 (10 µM), tryptase (30 nM) for 24 h. Results are mean ± SEM of the percentage of cells with an increased fluorescence 
intensity above the control (n = 3). Control values: BSA-stimulated, PE-anti-CD23 labeled, 10.9 ± 1.4 %; BSA-stimulated, PE-mouse IgG1, non-
immune, 0.5 ± 0.1 % (n = 3). *denotes significant increase in CD23 expression above the BSA control value.
Western blot analysis of CD23 after stimulation of IL-4, GM-CSF, IL-4/GM-CSF Figure 3
Western blot analysis of CD23 after stimulation of IL-4, GM-CSF, IL-4/GM-CSF. Alpha-smooth muscle isoactin pos-
itive huASMC (Clonetics) in T-75 flasks were starved for 24 h in 0.1% FBS containing medium M199. The cells were then stim-
ulated with BSA (1 µg/ml) (vehicle control), IL-4 (0.5 nM), GM-CSF (0.4 nM), or IL-4/GM-CSF (0.5 nM/0.4 nM) for 24 h. The 
cell lysates in RIPA buffer were subjected to western blot analysis for CD23. Mouse anti-human CD23 monoclonal antibody 
(clone M-L233, BD Biosciences, 1 µg/5 ml) was used as the primary antibody and anti-mouse horseradish peroxidase linked 
antibody as the secondary antibody (Amersham). The immunoreactive protein bands were detected by enhanced chemilumi-
nescence light (ECL) (Amersham). Paxillin mouse monoclonal IgG1 (Transduction Laboratories) was used as an irrelevant iso-
type control.
BSA IL-4 GM-CSF IL-4/GM-CSF
(1 µg/ml) (0.5) (0.4) (0.5/0/4) nM (24 h)
-CD23
−paxillin
45 kD -
68 kD -Clinical and Molecular Allergy 2005, 3:6 http://www.clinicalmolecularallergy.com/content/3/1/6
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reported that airway smooth muscle cells express the IL-
2Rγ c, the signaling unit of the IL-4 receptors.
Western blot analysis of IL-4Rα  and IL-2Rγ c in huASMC
lysates showed the presence of these receptor components
on huASMC. Figure 5 shows abundant expression of IL-
4Rα  and a low level expression of IL-2Rγ c protein on
huASMC. After stimulation of huASMC with IL-4 (0.4
nM) for 24 h, a two fold increase in γ c expression was
observed compared to the BSA vehicle control (Figure 6).
To confirm that IL-4 was activating the IL-4Rα  during the
stimulation of huASMC, we examined the phosphoryla-
tion of downstream STAT-6 by western blot. Human
ASMC were starved for 24 h and then stimulated with IL-
4 (0.4 nM) for fifteen minutes. Results of Western blot
revealed an approximately a four fold increase in intensity
Expression of CD23 in response to IL-4/GM-CSF is accompanied by changes in huASMC morphology Figure 4
Expression of CD23 in response to IL-4/GM-CSF is accompanied by changes in huASMC morphology. Alpha-
smooth muscle isoactin positive huASMC (Clonetics) in T-75 flasks were starved for 24 h in 0.1% FBS containing medium 
M199. The cells were then stimulated with either BSA or IL-4 (0.5 nM)/GM-CSF (0.4 nM) for 24 h, and stained with either anti-
smooth muscle-isoactin (A & B) or anti-CD23 antibody (C & D). Those cells stimulated with the combination of IL-4/GM-CSF 
demonstrated CD23 expression (D) and changes in cell morphology including depolymerization of isoactin fibers, cell spread-
ing, and membrane ruffling (B). Cells stimulated with BSA (vehicle for IL-4/GM-CSF) alone did not increase the expression of 
CD23 (C) nor changes in phenotype (A). These findings were confirmed by three independent observers.
BSA
IL-4/
GM-CSF
A A
B B
C C
D D
α-isoactin CD23
α-isoactin CD23
BSA
IL-4/
GM-CSF
Table 2: IL-4/GM-CSF Combination Increases Protein Content in 
huASMC.
Cytokine (nM) mg/106 cells (n = 3)
BSA (vehicle) 1.17 ± 0.08
IL-4 (0.5) 1.18 ± 0.01
GM-CSF 1.12 ± 0.03
IL-4 (0.5)/GM-CSF (0.4) 1.39 ± 0.02 *
Alpha-smooth muscle isoactin positive huASMC (Clonetics) in T-75 
flasks were starved for 24 h in 0.1% FBS containing medium M199. 
The cells were then stimulated with BSA (1 µg/ml)), IL-4 (0.5 nM), 
GM-CSF (0.4 nM), or IL-4/GM-CSF (0.4/0.5 nM) for 24 h. The cell 
lysates in RIPA buffer were analyzed for protein content using a 
commercially available BCA kit (Pierce). The optical density was read 
using a Bio-Kinetics EL-312 Microplate reader. Results are mean ± 
SEM (n = 3). *denotes value significantly different from the BSA 
vehicle treated control.Clinical and Molecular Allergy 2005, 3:6 http://www.clinicalmolecularallergy.com/content/3/1/6
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of the band for phosphorylated-STAT-6 in IL-4 stimulated
cells when compared to BSA control (Figure 7). This sup-
ports the role of an IL-4 mediated signal transduction
pathway involvement in CD23 upregulation in huASMC.
Discussion
In our study, we have demonstrated that CD23, the low
affinity IgE receptor, is upregulated on human airway
smooth muscle cells by the cytokines IL-4, GM-CSF, and
the combination of IL-4/GM-CSF. This upregulation of
CD23 by the combination of IL-4 and GM-CSF was
accompanied by an increase in cell volume and protein
content, cytoskeletal depolymerization, cell spreading
and membrane ruffling. Because ASMC require a dou-
bling time of 48 hours, the increase in protein content
could not be attributed to an increase in cell number.
Also, the increase in cell number in gate D seen with LTD4
was likely secondary to the effects of ethanol (Table 1).
Stimulation of huASMC by IL-4 caused an activation of
STAT-6 and an increase in γ c expression. Collectively, our
findings suggest that CD23 expression can be stimulated
by IL-4 and GM-CSF cytokines independent of IgE in
huASMC and the upregulation of CD23 may play a role in
cell migration and hypertrophy.
Previous studies have demonstrated an increase in CD23
expression in alveolar monocytes after stimulation with
IL-4 and GM-CSF [10]. In that study, the use of the indi-
vidual mediators alone did not increase the CD23 levels
to that of asthmatic patients suggesting a possible syner-
gistic role between IL-4 and GM-CSF. Our findings are
consistent with these in that the combination of IL-4 and
GM-CSF was most effective in upregulating CD23 in
huASMC. Not all TH2 cytokines are involved in this
process; IL-5 (0.4 nM) and IL-13 (0.4 nM) had no effect
on CD23 expression. Cysteinyl leukotriene LTD4 (10
µM), prostaglandin PGD2 (10 µM) and tryptase (30 nM)
did not induce CD23 expression on huASMC [26].
IL-4Rα  and IL-2Rγ c Expression in huASMC Figure 5
IL-4Rα  and IL-2Rγ c Expression in huASMC. A: IL-4Rα  and IL-2Rγ c expression in huASMC at baseline. Unstarved 
huASMC lysates were subjected to western blot analysis for IL-4Rα  and IL-2Rγ c using polyclonal anti-IL-4Rα  (1:500 dilution, 
Santa Cruz), or monoclonal anti-IL-2Rγ c (1:125 dilution, R&D Systems, Inc.). The nitrocellulose membranes were incubated 
with a 1:1,000 dilution of anti-rabbit or anti-mouse horseradish peroxidase linked whole antibody (Amersham). The immuno-
reactive protein bands were detected by ECL (Amersham). IL-2Rγ c is minimally expressed in huASMC while IL-4Rα  is 
expressed abundantly in huASMC.
1 M.W. (kD)  2
IB:   anti-IL-4Rα anti-IL-2Rγ c
-140
53 -
IL-4Rα  -
-I L - 2 R γ cClinical and Molecular Allergy 2005, 3:6 http://www.clinicalmolecularallergy.com/content/3/1/6
Page 9 of 12
(page number not for citation purposes)
We evaluated the effect of stimulation of huASMC with IL-
4 on phosphorylation of STAT-6 via the IL-4R which
would confirm the presence of the receptor in huASMC.
STAT-6 is a critical mediator of IL-4 stimulated gene acti-
vation, and it is regulated by both tyrosine and serine
kinases [27]. It has been shown in a mouse model that
STAT-6 binds the CD23a murine promoter, and STAT -/-
mice stimulated with IL-4 are unable to upregulate CD23.
This suggests STAT-6 is a critical mediator for IL-4 induced
upregulation of CD23 [28]. IL-4 along with CD40 medi-
ated signals are responsible for upregulation of CD23 on
B cells [14]. In this study, we have confirmed the
expression of the IL-4Rα  and a low level of common
gamma chain in huASMC and that after stimulation of
huASMC with IL-4, there was a two fold increase in γ c
chain expression (Figure 6). Phosphorylation of STAT-6
Upregulation of IL-2Rγ c Expression in huASMC by IL-4 and IL-4/GM-CSF Figure 6
Upregulation of IL-2Rγ c Expression in huASMC by IL-4 and IL-4/GM-CSF. Alpha-smooth muscle isoactin positive 
Human ASMC (Clonetics) in T-75 flasks were starved for 24 h in 0.1% FBS containing medium M199. The cells were then 
either stimulated with BSA (vehicle) (1 µg/ml), IL-4 (0.5 nM), GM-CSF (0.4 nM), or IL-4/GM-CSF (0.5 nM/0.4 nM) for 24 hours. 
The IL-4 and IL-4/GM-CSF stimulated cells had increased IL-2Rγ c expression compared to the BSA (vehicle) group. Fibronectin 
polyclonal rabbit antibody (Sigma) (1:250) was used as an irrelevant isotype control.
M.W. BSA IL-4 GM-CSF IL-4/GM-CSF
kD (1 µg/ml) (0.5 nM) (0.4 nM) (0.5/0.4 nM)
-IL-4Rα
−IL-2Rγc
-fibronectin
140 -
53 -
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Page 10 of 12
(page number not for citation purposes)
after stimulation with IL-4 for 15 min confirms that IL-4
has bound and activated the IL-4 receptor complex (Fig-
ure 7). It has been shown that the common gamma chain
is a functional β  chain of the IL-4 receptor complex in cer-
tain cells [27], and our data suggest that this is the case in
huASMC. Interestingly, IL-13 (4 nM, a concentration suf-
ficient to simulate huASMC proliferation, unpublished
observation) did not upregulate CD23. For proliferation
of ASMC by IL-13, IL-4Rα  and IL-13Rα 1 are required for
signal transduction and downstream activation of p44/42
extracellular regulated kinases (ERK, unpublished data).
Apparently, IL-4Rα  and IL-13Rα 1 engagement is not suf-
ficient for CD23 expression, further supporting the role of
γ c chain in CD23 expression by IL-4. The signs of signal
transduction in response to IL-4, and the increase in pro-
tein content of the cell in response to IL-4 and GM-CSF
combination (Table 2) represent activation of transcrip-
tion and translation of CD23 in this case. Coupling of
GM-CSF and its receptor complex is known to activate
ERK that may have contributed to the synergistic effect of
GM-CSF on CD23 expression.
CD23 expression was associated with changes in cell mor-
phology including depolymerization of isoactin fibers,
Phosphorylation of STAT-6 by IL-4 and IL-4/GM-CSF in huASMC Figure 7
Phosphorylation of STAT-6 by IL-4 and IL-4/GM-CSF in huASMC. Starved huASMC were incubated with either BSA 
vehicle control (1 µg/ml), IL-4 (0.5 nM), GM-CSF (0.4 nM), or IL-4/GM-CSF (0.5 nM/0.4 nM) for 15 minutes. Standard Western 
blot analyses were performed to detect STAT-6 and phosphorylated-STAT-6 (p-STAT-6) using a anti-STAT-6 polyclonal rabbit 
antibody (Calbiochem) and anti-p-STAT-6 polyclonal rabbit antibody (Calbiochem). Anti-rabbit horseradish peroxidase linked 
antibody was used as the secondary antibody. Protein bands were detected by ECL. STAT-6 was abundantly expressed by all 
four groups, while p-STAT-6 was only expressed in the IL-4 and IL-4/GM-CSF groups. Fibronectin polyclonal rabbit antibody 
(Sigma) was used as an irrelevant isotype control and was abundantly expressed in all four groups.
MW BSA IL-4 GM-CSF IL-4/GM-CSF
(kD) (1 µg/ml) (0.5nM) (0.4nM) (0.5/0.4nM)
15min Incubation
-p-stat 6
-stat-6
-fibronectin
110 -
110 -
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cell spreading, and membrane ruffling (Figure 4B &4D).
Actin in ASMC is in a dynamic state and undergoes
polymerization-depolymerization during the contraction-
relaxation cycle [29,30]. Membrane ruffling and cell
migration involve signaling pathways including PI3-
kinase, Rac and other Rho family G protein members in a
variety of cell types, including vascular smooth muscle
cells. Rac has an essential role in cell migration and regu-
lation of the actin cytoskeleton [31,32]. Moreover, ASMC
are capable of switching their phenotypes from contractile
to synthetic phenotype that is mediated by Rho kinases
[32,33].
In summary, we have demonstrated that the low affinity
IgE receptor can be induced on huASMC by specific
cytokines including IL-4, GM-CSF, and the combination
of IL-4/GM-CSF. The combination of IL-4/GM-CSF also
induced morphologic changes in the ASMC that may
contribute to the synthetic function or migration. In addi-
tion, IL-4 and IL-4/GM-CSF stimulation of huASMC
increased the protein content of the cell, suggesting
hypertrophy.
Conclusion
T helper type 2 cytokines including IL-4 have major role
in asthma pathogenesis. GM-CSF is a hemopoetic growth
factor, mostly released by activated monocytes and T cells.
Additional sources of GM-CSF include epithelium of asth-
matic airways [34] and human airway smooth muscle
cells [6,35]. Therefore, the effect of GM-CSF on CD23
expression can be both via paracrine and autocrine mech-
anisms. Previous studies by Hakonarson et al. [16,17]
have shown that upregulation of the CD23 receptor has
been associated with proasthmatic changes in agonist-
mediated ASM constrictor and relaxant responsiveness.
Our study suggests that CD23 expression is associated
with elements of hypertrophy (i.e. an increase in cell vol-
ume and protein content), thus consistent with their find-
ings. Inhaled corticosteroids, the mainstay in treatment of
asthma, effectively reduce inflammation and remodeling
of the epithelium and basement membrane. However, no
agents have been proven effective in reducing smooth
muscle mass in asthmatic patients. Recent study results on
anti-CD23 therapy showed decrease in serum IgE. Further
studies to intervene the upregulation of CD23 expression
by cytokines IL-4 and GM-CSF may open a new avenue to
target smooth muscle hypertrophy, an important element
of severe asthma [2].
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